RGNX – regenxbio inc. (US:NASDAQ)
Stock Stats
News
REGENXBIO Inc. (NASDAQ: RGNX) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $35.00 price target on the stock.
REGENXBIO Inc. (NASDAQ: RGNX) had its price target lowered by analysts at HC Wainwright from $40.00 to $36.00. They now have a "buy" rating on the stock.
REGENXBIO Inc. (NASDAQ: RGNX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.
REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA [Yahoo! Finance]
REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
Form 424B5 REGENXBIO Inc.
Form 8-K REGENXBIO Inc. For: Dec 09
Form SC 13G/A REGENXBIO Inc. Filed by: Redmile Group, LLC
Form SC 13G/A REGENXBIO Inc. Filed by: VANGUARD GROUP INC
Form 10-Q REGENXBIO Inc. For: Sep 30
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.